Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
J Eur Acad Dermatol Venereol ; 37 Suppl 5: 18-26, 2023 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-37092275

RESUMEN

BACKGROUND: Moderate to severe AD can be successfully managed by systemic treatments. Current guidelines also recommend emollients or emollients 'plus' and eudermic cleansers for all AD patients to improve the skin barrier and provide anti-irritant and anti-pruritic effects. OBJECTIVES: To investigate the efficacy of skin care (in addition to systemic treatment) with an Emollient 'plus' balm designed to improve the skin barrier and skin microbiome plus a corresponding syndet compared to usual commercial emollients and cleansers. METHODS: In a randomized controlled multicenter study, patients with moderate to severe AD (Severity scoring of atopic dermatitis [SCORAD] score ≥ 40) receiving systemic treatment (cyclosporin A, dupilumab or a Janus kinase inhibitor) were randomized 1:1 to apply twice daily for 10 weeks Emollient 'plus' after pre-cleaning with the syndet (Emollient 'plus' group) or to continue with their usual emollient and cleanser (Control group). Assessments included SCORAD, pruritus on a Visual Analog Scale, Dermatology quality of life questionnaire (DLQI), efficacy and tolerance questionnaires. RESULTS: Included were 57 patients with mean age of 38 years (range 19-70 years). The mean amount of emollient used after 10 weeks was 447.3 g (range 29-1099 g) and 613.2 g (range 97-2565 g) for the Emollient 'plus' versus the Control, respectively (p = 0.0277). After 10 weeks, subjects in the Emollient 'plus' had a significantly greater reduction in current pruritus (p = 0.0277) and a greater reduction in some DLQI items compared to the Control group. CONCLUSIONS: In patients with moderate to severe AD receiving systemic treatment, the Emollient 'plus' regimen significantly improved pruritus and quality of life items compared to the control, while using 23% less product over a 10-week period. These results stress the importance of daily use of emollients, especially emollients 'plus' to improve signs, symptoms and quality of life in patients with AD.


Asunto(s)
Dermatitis Atópica , Humanos , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Dermatitis Atópica/tratamiento farmacológico , Dermatitis Atópica/diagnóstico , Emolientes/uso terapéutico , Detergentes , Calidad de Vida , Resultado del Tratamiento , Prurito/tratamiento farmacológico , Prurito/etiología , Cuidados de la Piel , Índice de Severidad de la Enfermedad
2.
Skin Pharmacol Physiol ; 35(2): 77-86, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-34348349

RESUMEN

INTRODUCTION: Bathing in the Blue Lagoon (BL) in Iceland benefits patients with psoriasis. Accordingly, the BL water contains algae with biological activities that improve skin barrier function and affect T-cell responses relevant for psoriasis. Bathing in the BL is also becoming increasingly popular among healthy individuals and anecdotal evidence suggests positive effects on uneven skin pigmentation. OBJECTIVE: The aim of the study was to address the impact of BL algae on skin pigmentation. METHODS: In this work, in vitro gene expression studies in melanocytes and a noninvasive in vivo study were conducted. RESULTS: We here report that normal human epidermal melanocytes, which had been treated with nontoxic concentrations of BL algae, show a significantly reduced expression of α melanocyte-stimulating hormone-induced expression of genes important for melanin synthesis, such as tyrosinase, tyrosinase-related protein 1, dopachrome tautomerase, melan A protein, and pre-melanosome protein. This in vitro observation prompted us to conduct a randomized, double-blind, intra-individual, comparative split-face in vivo study, in which 60 volunteers with pre-existing facial pigment spots were treated twice daily with a BL algae containing serum or a vehicle control. We found that constitutive skin pigmentation as determined by colorimetry (individual typology angle and luminescence) did not differ significantly between vehicle- and serum-treated skin sites. In marked contrast, digital photography under cross-polarized lighting and RBX technology (VISIA CR) revealed that the number of pigment spots in the serum-treated face decreased significantly compared to the vehicle-treated side. CONCLUSION: Thus, BL algae can affect human melanocyte function in vitro and reduce uneven facial skin pigmentation in vivo.


Asunto(s)
Melanocitos , Pigmentación de la Piel , Método Doble Ciego , Humanos , Melaninas/metabolismo , Monofenol Monooxigenasa/metabolismo , Piel/metabolismo
3.
Photodermatol Photoimmunol Photomed ; 36(3): 219-225, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32072695

RESUMEN

BACKGROUND: Photoprotection of human skin is determined as the capacity of sunscreens to prevent ultraviolet (UV) B radiation-induced erythema and UVA radiation-induced pigmentation. It is unequivocal that, in addition to sunscreens, oral supplementation with carotenoids can protect human skin against UVB radiation-induced erythema. It is not known if this is also the case for UVA radiation-induced pigmentation. OBJECTIVE: To clinically evaluate the photoprotective effects of daily supplementation with carotenoids against UVA radiation-induced pigmentation. METHODS: In this double-blind, placebo-controlled trial, 60 subjects (Fitzpatrick types II-IV) were randomized to receive Nutrilite™ Multi Carotene supplement or placebo for 12 weeks. UVB-induced minimal erythemal dose (MED), UVA-induced minimal persistent pigmentation dose (MPPD) and skin carotenoid levels were measured at baseline, 4, 8, and 12 weeks of intervention. Skin color was evaluated by expert clinical graders and by colorimetry. Carotenoid levels in the skin were measured by the Biozoom® device. RESULTS: In the intervention group, a significant increase in comparison with the placebo group was observed in (a) skin carotenoid levels, (b) UVB-induced MED, and (c) UVA-induced MPPD values obtained by colorimetry. CONCLUSION: Daily supplementation with carotenoids protects human skin against both UVB-induced erythema and UVA-induced pigmentation.


Asunto(s)
Carotenoides/uso terapéutico , Pigmentación de la Piel/efectos de los fármacos , Rayos Ultravioleta/efectos adversos , Administración Oral , Adulto , Carotenoides/administración & dosificación , Carotenoides/análisis , Método Doble Ciego , Eritema/etiología , Eritema/prevención & control , Humanos , Piel/química , Pigmentación de la Piel/efectos de la radiación , Adulto Joven
4.
Skin Pharmacol Physiol ; 33(1): 9-16, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31509849

RESUMEN

INTRODUCTION: Skin ageing involves senescent fibroblast accumulation, disturbance in extracellular matrix (ECM) homeostasis, and decreased collagen synthesis. OBJECTIVE: to assess a cell therapy product for aged skin (RCS-01; verum) consisting of ~25 × 106 cultured, autologous cells derived from anagen hair follicle non-bulbar dermal sheath (NBDS). METHODS: For each subject in the verum group, 4 areas of buttock skin were injected intradermally 1 or 3 times at monthly intervals with RCS-01, cryomedium, or needle penetration without injection; in the placebo group RCS-01 was replaced by cryomedium. The primary endpoint was assessment of local adverse event profiles. As secondary endpoints, expression of genes related to ECM homeostasis was assessed in biopsies from randomly selected volunteers in the RCS-01 group taken 4 weeks after the last injection. -Results: Injections were well tolerated with no severe adverse events reported 1 year after the first injection. When compared with placebo-treated skin, a single treatment with RCS-01 resulted in a significant upregulation of TGFß1, CTGF, COL1A1, COL1A2, COL3A1, and lumican mRNA expression. LIMITATIONS: The cohort size was insufficient for dose -ranging evaluation and subgroup analyses of efficacy. CONCLUSIONS: RCS-01 therapy is well tolerated and associated with a gene expression response consistent with an improvement of ECM homeostasis.


Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos , Folículo Piloso/citología , Envejecimiento de la Piel , Colágeno Tipo I/genética , Cadena alfa 1 del Colágeno Tipo I , Colágeno Tipo III/genética , Factor de Crecimiento del Tejido Conjuntivo/genética , Método Doble Ciego , Femenino , Regulación de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Envejecimiento de la Piel/genética , Transcriptoma , Factor de Crecimiento Transformador beta1/genética , Trasplante Autólogo
5.
PLoS One ; 14(8): e0219996, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31369574

RESUMEN

The Medical Monitoring Project (MMP) is an HIV surveillance system that provides national estimates of HIV-related behaviors and clinical outcomes. When first implemented, MMP excluded persons living with HIV not receiving HIV care. This analysis will describe new case-surveillance-based methods to identify and recruit persons living with HIV who are out of care and at elevated risk for mortality and ongoing HIV transmission. Stratified random samples of all persons living with HIV were selected from the National HIV Surveillance System in five public health jurisdictions from 2012-2014. Sampled persons were located and contacted through seven different data sources and five methods of contact to collect interviews and medical record abstractions. Data were weighted for non-response and case reporting delay. The modified sampling methodology yielded 1159 interviews (adjusted response rate, 44.5%) and matching medical record abstractions for 1087 (93.8%). Of persons with both interview and medical record data, 264 (24.3%) would not have been included using prior MMP methods. Significant predictors were identified for successful contact (e.g., retention in care, adjusted Odds Ratio [aOR] 5.02; 95% Confidence Interval [CI] 1.98-12.73), interview (e.g. moving out of jurisdiction, aOR 0.24; 95% CI: 0.12-0.46) and case reporting delay (e.g. rural residence, aOR 3.18; 95% CI: 2.09-4.85). Case-surveillance-based sampling resulted in a comparable response rate to existing MMP methods while providing information on an important new population. These methods have since been adopted by the nationally representative MMP surveillance system, offering a model for public health program, research and surveillance endeavors seeking inclusion of all persons living with HIV.


Asunto(s)
Infecciones por VIH/prevención & control , VIH/aislamiento & purificación , Atención al Paciente/métodos , Atención al Paciente/estadística & datos numéricos , Carga Viral , Adulto , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Infecciones por VIH/virología , Humanos , Masculino , Persona de Mediana Edad , Vigilancia de la Población , Estados Unidos/epidemiología
6.
Skin Pharmacol Physiol ; 32(2): 101-108, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30836363

RESUMEN

BACKGROUND: Our previous double-blinded, placebo-controlled cross-over study indicated that a nutritional supplement named lycopene-rich tomato nutrient complex (TNC) can protect from UVA1-induced (340-400 nm) and UVA- (320-400 nm)/UVB-induced (280-320 nm) upregulation of molecular markers associated with oxidative stress, inflammation, and ageing. OBJECTIVES: in the current double-blind, randomized, placebo-controlled multicenter study, we analyze whether a similar, synergistic carotenoid-rich TNC can protect from broadband UVB-induced threshold erythema formation assessed as increase in minimal erythemal dose (MED) reading, the intensity of erythema formation, and the upregulation of molecular markers associated with inflammation and immunosuppression, and whether this correlates with carotenoid blood levels. METHODS: One hundred and forty-nine healthy volunteers were randomized to two groups and subjected to a 5-week washout phase, followed by a 12-week treatment phase receiving either 15 mg lycopene, 5.8 mg phytoene and phytofluene, 0.8 mg ß-carotene, 5.6 mg tocopherols from tomato extract, and 4 mg carnosic acid from rosemary extract per day or placebo made from medium-chain triglycerides. At the end of each phase, MED determination, UVB irradiation, chromametry, biopsies, and blood samples were undertaken. RESULTS: The active supplement was well tolerated. Interestingly, no significant difference was seen in the MED between the active-supplement and placebo groups, as determined by visual grading by expert assessors. Of note, the carotenoid-containing supplement significantly protected against UVB-induced erythema formation measured as Δa* after the intervention minus Δa* after the washout phase as compared to the placebo. Moreover, intake of the active supplement significantly protected against UVB-induced upregulation of IL6 and TNFα as compared with the intake of placebo. Lastly, carotenoid plasma levels were significantly increased. CONCLUSION: This well-tolerated carotenoid-containing supplement significantly protected against UVB-induced erythema formation and upregulation of proinflammatory cytokines in healthy volunteers.


Asunto(s)
Antioxidantes/farmacología , Carotenoides/farmacología , Suplementos Dietéticos , Eritema/prevención & control , Fitoquímicos/farmacología , Protectores contra Radiación/farmacología , Solanum lycopersicum/química , Rayos Ultravioleta/efectos adversos , Adulto , Citocinas/genética , Método Doble Ciego , Eritema/genética , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/efectos de la radiación , Humanos , Masculino , Persona de Mediana Edad , Piel/efectos de los fármacos , Piel/metabolismo , Piel/efectos de la radiación , Adulto Joven
7.
Public Health Rep ; 133(2): 147-154, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29486143

RESUMEN

INTRODUCTION: Human immunodeficiency virus (HIV) case surveillance and other health care databases are increasingly being used for public health action, which has the potential to optimize the health outcomes of people living with HIV (PLWH). However, often PLWH cannot be located based on the contact information available in these data sources. We assessed the accuracy of contact information for PLWH in HIV case surveillance and additional data sources and whether time since diagnosis was associated with accurate contact information in HIV case surveillance and successful contact. MATERIALS AND METHODS: The Case Surveillance-Based Sampling (CSBS) project was a pilot HIV surveillance system that selected a random population-based sample of people diagnosed with HIV from HIV case surveillance registries in 5 state and metropolitan areas. From November 2012 through June 2014, CSBS staff members attempted to locate and interview 1800 sampled people and used 22 data sources to search for contact information. RESULTS: Among 1063 contacted PLWH, HIV case surveillance data provided accurate telephone number, address, or HIV care facility information for 239 (22%), 412 (39%), and 827 (78%) sampled people, respectively. CSBS staff members used additional data sources, such as support services and commercial people-search databases, to locate and contact PLWH with insufficient contact information in HIV case surveillance. PLWH diagnosed <1 year ago were more likely to have accurate contact information in HIV case surveillance than were PLWH diagnosed ≥1 year ago ( P = .002), and the benefit from using additional data sources was greater for PLWH with more longstanding HIV infection ( P < .001). PRACTICE IMPLICATIONS: When HIV case surveillance cannot provide accurate contact information, health departments can prioritize searching additional data sources, especially for people with more longstanding HIV infection.


Asunto(s)
Exactitud de los Datos , Recolección de Datos/métodos , Infecciones por VIH/diagnóstico , Infecciones por VIH/terapia , Vigilancia de la Población/métodos , Informática en Salud Pública/métodos , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Infecciones por VIH/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Estados Unidos/epidemiología
8.
Skin Pharmacol Physiol ; 29(1): 13-7, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26492562

RESUMEN

Nutritional strategies to benefit skin health are of growing importance. Current approaches mainly involve nutritional supplements containing antioxidants which were initially designed to protect human skin against ultraviolet radiation-induced damage. Within recent years, however, a growing number of studies suggests that the beneficial effects of these products clearly extend beyond photoprotection. In this review we take the nutritional supplement Pycnogenol®, which is based on an extract prepared from French marine pine bark extract, as an example to illustrate this development. Accordingly, the existing data provide compelling evidence that Pycnogenol® intake does not only provide photoprotection, but may be used to (i) reduce hyperpigmentation of human skin and (ii) improve skin barrier function and extracellular matrix homeostasis.


Asunto(s)
Flavonoides/farmacología , Pinus , Extractos Vegetales/farmacología , Protectores Solares/farmacología , Animales , Suplementos Dietéticos , Humanos , Corteza de la Planta , Piel/efectos de los fármacos , Piel/metabolismo , Pigmentación de la Piel/efectos de los fármacos
9.
Photochem Photobiol ; 91(1): 248-50, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25349107

RESUMEN

Infrared A radiation (IRA) from solar sunlight contributes to photoaging of human skin, e.g. by upregulating MMP-1 expression in dermal fibroblasts, indicating the need for photoprotection of human skin against IRA. Up to now, however, there has been no controlled study to show that effective protection of human skin against IRA radiation is possible. Here, we have conducted a randomized, controlled, double-blinded prospective study in 30 healthy volunteers to assess the capacity of an SPF 30 sunscreen versus the same sunscreen supplemented with an antioxidant cocktail containing grape seed extract, vitamin E, ubiquinone and vitamin C to protect human skin against IRA radiation-induced MMP-1 upregulation. As expected, exposure to IRA radiation significantly upregulated MMP-1 expression, as compared to unirradiated skin, and this response was significantly reduced, if the SPF30 sunscreen plus the antioxidant cocktail had been applied prior to IRA radiation. In contrast, treatment of human skin with the SPF30 sunscreen alone did not provide significant protection. These results indicate that topically applied antioxidants effectively protect human skin against IRA radiation and that regular sunscreens need to be supplemented with specific antioxidants in order to achieve IRA photoprotection.


Asunto(s)
Antioxidantes/administración & dosificación , Rayos Infrarrojos , Piel/efectos de los fármacos , Piel/efectos de la radiación , Administración Tópica , Método Doble Ciego , Humanos
10.
Photodermatol Photoimmunol Photomed ; 30(2-3): 167-74, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24433486

RESUMEN

Photoprotection of human skin by means of sunscreens or daily skin-care products is traditionally centered around the prevention of acute (e.g. sunburn) and chronic (e.g. skin cancer and photoaging) skin damage that may result from exposure to ultraviolet rays (UVB and UVA). Within the last decade, however, it has been appreciated that wavelengths beyond the ultraviolet spectrum, in particular visible light and infrared radiation, contribute to skin damage in general and photoaging of human skin in particular. As a consequence, attempts have been made to develop skin care/sunscreen products that not only protect against UVB or UVA radiation but provide photoprotection against visible light and infrared radiation as well. In this article, we will briefly review the current knowledge about the mechanisms responsible for visible light/infrared radiation-induced skin damage and then, based on this information, discuss strategies that have been successfully used or may be employed in the future to achieve photoprotection of human skin beyond ultraviolet radiation. In this regard we will particularly focus on the use of topical antioxidants and the challenges that result from the task of showing their efficacy.


Asunto(s)
Antioxidantes/uso terapéutico , Cosméticos/uso terapéutico , Rayos Infrarrojos/efectos adversos , Piel , Quemadura Solar/prevención & control , Protectores Solares/uso terapéutico , Rayos Ultravioleta/efectos adversos , Administración Tópica , Humanos
11.
Photodermatol Photoimmunol Photomed ; 30(4): 189-94, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24283388

RESUMEN

BACKGROUND: Polymorphic light eruption (PLE) is the most common photodermatosis. Little is known about the efficacy of systemic photoprotection provided by nutritional supplements in PLE patients. PURPOSE: The purpose of this study was to assess efficacy of nutritional supplement containing lycopene, ß-carotene, and Lactobacillus johnsonii to diminish skin lesions induced by 'photoprovocation' testing in PLE patients. METHODS: In this randomized, placebo-controlled, double-blinded study, 60 PLE patients were supplemented with the nutritional supplement or placebo. For inducing skin lesions, patient skin was exposed to single daily doses of 100 J/cm2 ultraviolet A1 (UVA1) for two consecutive days. Skin lesions were evaluated using a PLE score. Skin biopsies were taken before and after supplementation from unexposed and exposed skin, and intercellular adhesion molecule 1 (ICAM-1) mRNA expression was assessed by real-time polymerase chain reaction. RESULTS: Prior to supplementation, skin lesions were induced in all patients with comparable PLE scores. After 12 weeks, intake of the supplement significantly reduced the PLE score after one exposure as compared with patients taking placebo (P<0.001). After two exposures, these differences were no longer significant. At a molecular level, the development of skin lesions was associated with an increased expression of ICAM-1 mRNA, which was significantly reduced after supplementation (P=0.022), but not with placebo. CONCLUSION: The nutritional supplement provides protection against the development of UVA-induced PLE lesions at clinical and molecular levels.


Asunto(s)
Carotenoides/administración & dosificación , Suplementos Dietéticos , Lactobacillus , Trastornos por Fotosensibilidad/prevención & control , Protectores contra Radiación/administración & dosificación , Vitaminas/administración & dosificación , beta Caroteno/administración & dosificación , Administración Oral , Adolescente , Adulto , Método Doble Ciego , Femenino , Humanos , Molécula 1 de Adhesión Intercelular/metabolismo , Licopeno , Masculino , Persona de Mediana Edad , Trastornos por Fotosensibilidad/metabolismo , Trastornos por Fotosensibilidad/patología , Piel/metabolismo , Piel/patología , Rayos Ultravioleta
12.
J Invest Dermatol ; 132(6): 1561-72, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22418868

RESUMEN

Urea is an endogenous metabolite, known to enhance stratum corneum hydration. Yet, topical urea anecdotally also improves permeability barrier function, and it appears to exhibit antimicrobial activity. Hence, we hypothesized that urea is not merely a passive metabolite, but a small-molecule regulator of epidermal structure and function. In 21 human volunteers, topical urea improved barrier function in parallel with enhanced antimicrobial peptide (AMP; LL-37 and ß-defensin-2) expression. Urea stimulates the expression of, and is transported into, keratinocytes by two urea transporters (UTs), UT-A1 and UT-A2, and by aquaporins 3, 7, and 9. Inhibitors of these UTs block the downstream biological effects of urea, which include increased mRNA and protein levels of (i) transglutaminase-1, involucrin, loricrin, and filaggrin, (ii) epidermal lipid synthetic enzymes, and (iii) cathelicidin/LL-37 and ß-defensin-2. Finally, we explored the potential clinical utility of urea, showing that topical urea applications normalized both barrier function and AMP expression in a murine model of atopic dermatitis. Together, these results show that urea is a small-molecule regulator of epidermal permeability barrier function and AMP expression after transporter uptake, followed by gene regulatory activity in normal epidermis, with potential therapeutic applications in diseased skin.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/genética , Permeabilidad de la Membrana Celular/efectos de los fármacos , Dermatitis Atópica/tratamiento farmacológico , Epidermis/metabolismo , Regulación de la Expresión Génica/efectos de los fármacos , Urea/farmacocinética , Adulto , Animales , Péptidos Catiónicos Antimicrobianos/metabolismo , Acuaporina 3/genética , Acuaporina 3/metabolismo , Acuaporinas/genética , Acuaporinas/metabolismo , Diferenciación Celular/fisiología , Permeabilidad de la Membrana Celular/fisiología , Dermatitis Atópica/metabolismo , Dermatitis Atópica/fisiopatología , Células Epidérmicas , Femenino , Proteínas Filagrina , Regulación de la Expresión Génica/fisiología , Humanos , Queratinocitos/citología , Masculino , Proteínas de Transporte de Membrana/genética , Proteínas de Transporte de Membrana/metabolismo , Ratones , Ratones Pelados , Persona de Mediana Edad , Cultivo Primario de Células , Agua/metabolismo , Adulto Joven , Transportadores de Urea
13.
Cutis ; 90(6): 321-6, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23409485

RESUMEN

The damaging effects of UVA radiation have been well-documented. UVA radiation is known to induce molecular, cellular, and clinical damage. Such harm may lead to photoaging, immune system depression, altered gene expression, or oncogene and tumor suppressor gene modulation, all of which are partly responsible for the development of skin cancer. In parallel to an increased understanding of the added damage caused by UVA radiation, progress has been made in sunscreen formulation. A variety of UVA filters are now available for formulators to combine with UVB filters to reach high-level photostable protection using a minimum concentration of active ingredients. The efficacy of products that contain these UV filter combinations usually is determined by noninvasive assessments, which cause either UVA-induced erythema or skin pigmentation. However, the biologic relevance of these end points for UVA radiation-induced skin damage is unknown. In our study, we confirm that the assessment of UVA radiation-induced gene expression in skin specimens obtained from UVA-irradiated human skin by quantitative real-time polymerase chain reaction is a sensitive, reliable, and robust method to prove the efficacy of 2 daily moisturizers containing broad-spectrum sunscreen. Specifically, we demonstrate in vivo that topical application of a daily moisturizer with broad-spectrum sunscreen prevents UVA radiation-induced transcriptional expression of genes that are directly linked to skin aging (ie, matrix metalloproteinase 1 [MMP-1]) and also reflect the skin's antioxidative stress defense response (ie, catalase [CAT], superoxide dismutase [SOD], glutathione peroxidase [GPx]). Furthermore, we demonstrate that the protection against UV-induced skin damage provided by products with different sun protection factor (SPF) but the same UVA protection factor (UVA-PF) is similar, which emphasizes the importance of high UVA protection to maintain unaltered essential biologic functions. These data indicate that the use of a daily moisturizer containing broad-spectrum sunscreen with a well-balanced SPF/UVA-PF ratio on a regular basis is beneficial for human skin.


Asunto(s)
Expresión Génica/efectos de la radiación , Traumatismos por Radiación/genética , Crema para la Piel/uso terapéutico , Protectores Solares/uso terapéutico , Rayos Ultravioleta/efectos adversos , Administración Cutánea , Catalasa/genética , Relación Dosis-Respuesta en la Radiación , Método Doble Ciego , Glutatión Peroxidasa/genética , Humanos , Metaloproteinasa 1 de la Matriz/genética , Traumatismos por Radiación/prevención & control , Piel/enzimología , Piel/efectos de la radiación , Crema para la Piel/administración & dosificación , Estadísticas no Paramétricas , Factor de Protección Solar , Protectores Solares/administración & dosificación , Superóxido Dismutasa/genética , Transcripción Genética/efectos de la radiación
14.
Exp Dermatol ; 21(2): 140-6, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22142309

RESUMEN

Uneven skin pigmentation is a significant cosmetic concern, and the identification of topically applicable molecules to address this issue is of general interest. We report that the tetrapeptide PKEK (Pro-Lys-Glu-Lys) can exert skin whitening effects based on one in vitro and four double-blinded vehicle-controlled in vivo studies. (i) Treatment of human keratinocytes with PKEK significantly reduced UVB-stimulated mRNA expression of interleukin (IL)-6, IL-8 and TNF-α and, most importantly, proopiomelanocorticotropin (POMC), i.e. a gene encoding the pigmentation-inducing soluble mediator α- (α-MSH). (ii) PKEK treatment significantly inhibited UVB-induced upregulation of genes encoding for IL-1α, IL-6, IL-8, TNF-α as well as POMC and tyrosinase in 10 healthy volunteers pretreated with PKEK for 4 weeks once daily. (iii) In a study enrolling 39 Caucasian women, facial pigment spots significantly faded after 6 weeks when PKEK was combined with the skin whitener sodium ascorbyl phosphate (SAP), whereas PKEK or SAP alone led to less pronounced fading of the pigment spots. (iv) Addition of PKEK enhanced the skin whitening potency of a SAP-containing preparation if applied for 8 weeks to the back of hands of 19 Caucasians. (v) 27 Japanese women were treated on their faces twice daily with an SAP only or a PKEK+SAP-containing formulation for 8 weeks. Application of PKEK+SAP significantly reduced skin pigmentation by 26% and by 18% according to SCINEXA score. We demonstrate that PKEK has the capacity to reduce UVB-induced skin pigmentation and may be suited to serve as a skin tone-modulating agent in cosmetic products.


Asunto(s)
Oligopéptidos/farmacología , Oligopéptidos/uso terapéutico , Pigmentación de la Piel/efectos de los fármacos , Piel/efectos de los fármacos , Adulto , Anciano , Ácido Ascórbico/análogos & derivados , Ácido Ascórbico/farmacología , Ácido Ascórbico/uso terapéutico , Pueblo Asiatico , Células Cultivadas , Colorimetría , Método Doble Ciego , Femenino , Expresión Génica/efectos de los fármacos , Expresión Génica/efectos de la radiación , Humanos , Interleucina-1beta/genética , Interleucina-6/genética , Interleucina-8/genética , Queratinocitos/efectos de los fármacos , Queratinocitos/metabolismo , Queratinocitos/efectos de la radiación , Masculino , Persona de Mediana Edad , Monofenol Monooxigenasa/genética , Proopiomelanocortina/metabolismo , Piel/anatomía & histología , Piel/metabolismo , Piel/efectos de la radiación , Envejecimiento de la Piel/efectos de los fármacos , Pigmentación de la Piel/efectos de la radiación , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/genética , Rayos Ultravioleta , Población Blanca
15.
Exp Dermatol ; 20(7): 602-4, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21692860

RESUMEN

The 'matrikine' concept claims that processing of the precursors for collagen results in the formation of peptides such as KTTKS which in turn augments extracellular matrix (ECM) production. In the present study, we show the development of an anti-ageing active from an in silico approach by molecular design resulting in the tetrapeptide GEKG derived from ECM proteins. The efficacy of the peptide to significantly induce collagen production of the protein level and mRNA level has been demonstrated in vitro in human dermal fibroblasts and in vivo in a double-blind, randomized, placebo-controlled study enroling 10 volunteers with an average age of 48.2 years. The effect of GEKG on facial wrinkles was studied in 30 volunteers using state of the art fringe projection, which allows determination of surface roughness in three-dimensions. Here, only GEKG but not the placebo was able to significantly decrease skin roughness as a measure for wrinkles.


Asunto(s)
Matriz Extracelular/metabolismo , Oligopéptidos/farmacología , Envejecimiento de la Piel/efectos de los fármacos , Adulto , Células Cultivadas , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Cadena alfa 1 del Colágeno Tipo I , Fármacos Dermatológicos/farmacología , Fármacos Dermatológicos/uso terapéutico , Método Doble Ciego , Elasticidad/efectos de los fármacos , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Fibronectinas/genética , Fibronectinas/metabolismo , Expresión Génica/genética , Glucuronosiltransferasa/genética , Humanos , Hialuronano Sintasas , Ácido Hialurónico/metabolismo , Oligopéptidos/uso terapéutico , Procolágeno/metabolismo , Piel/efectos de los fármacos , Piel/metabolismo , Fenómenos Fisiológicos de la Piel/efectos de los fármacos
16.
Exp Dermatol ; 20(6): 477-82, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21410776

RESUMEN

The efficacy of sunscreens to protect against ultraviolet (UV) A radiation is usually assessed by measuring erythema formation and pigmentation. The biological relevance of these endpoints for UVA-induced skin damage, however, is not known. We therefore carried out two complementary studies to determine UVA protection provided by a broad-spectrum sunscreen product at a molecular level by studying UVA radiation-induced gene expression. One study was performed on human reconstructed skin in vitro with a semi-global gene expression analysis of 227 genes in fibroblasts and 244 in keratinocytes. The second one was conducted in vivo in human volunteers and focused on genes involved in oxidative stress response and photo-ageing (haeme oxygenase-1, superoxide dismutase-2, glutathione peroxidase, catalase, matrix metalloproteinase-1). In-vitro UVA radiation induced modulation of genes involved in extracellular matrix homeostasis, oxidative stress, heat shock responses, cell growth, inflammation and epidermal differentiation. Sunscreen pre-application abrogated or significantly reduced these effects, as underlined by unsupervised clustering analysis. The in vivo study confirmed that the sunscreen prevented UVA radiation-induced transcriptional expression of the five studied genes. These findings indicate the high efficacy of a broad-spectrum sunscreen in protecting human skin against UVA-induced gene responses and suggest that this approach is a biologically relevant complement to existing methods.


Asunto(s)
Expresión Génica/efectos de los fármacos , Expresión Génica/efectos de la radiación , Piel/efectos de los fármacos , Piel/efectos de la radiación , Protectores Solares/farmacología , Rayos Ultravioleta/efectos adversos , Catalasa/genética , Glutatión Peroxidasa/genética , Hemo-Oxigenasa 1/genética , Humanos , Técnicas In Vitro , Metaloproteinasa 1 de la Matriz/genética , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/genética , Estrés Oxidativo/efectos de la radiación , Piel/metabolismo , Envejecimiento de la Piel/efectos de los fármacos , Envejecimiento de la Piel/genética , Envejecimiento de la Piel/efectos de la radiación , Superóxido Dismutasa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...